Biocytogen (688796.SH) Latest Stock News - Major News Analysis - Longbridge

Quote List Quote List

Event Tracking

Dec5

Biosceptre and Partner Ideaya Obtain FDA Approval to Advance IDE034 Phase I Clinical Trial for B7H3/PTK7 Bispecific Antibody Drug Conjugate

01:02

Sep25

Biocytogen released FY2025 Q1 earnings on September 25, 2025 (BJT) with actual revenue of CNY 310.48 M and EPS of CNY 0.0605

15:00

688796.SH released FY2025 Q2 earnings on September 25 (BJT), actual revenue CNY 310.48 M, actual EPS CNY 0.0605

15:00

Biocytogen released FY2024 Q2 earnings on September 25 (BJT), actual revenue CNY 205.25 M, actual EPS CNY -0.0636

15:00

Biocytogen released FY2025 Semi-Annual earnings on September 25 (BJT), actual revenue CNY 620.96 M, actual EPS CNY 0.1211

15:00

Biocytogen released FY2024 Semi-Annual Earnings on September 25 (BJT), actual revenue CNY 410.5 M (forecast CNY 410.21 M), actual EPS CNY -0.1272

15:00

Schedules & Filings

Schedules

Filings

Sep25

Earning Release(CST)

FY2025 Q2 Earning Release (CNY) Revenue 310.48 M, Net Income 24 M, EPS 0.0605

Aug28

Earning Release(CST)

FY2025 Semi-Annual Earning Release

Apr23

Earning Release(CST)

FY2024 Q4 Earning Release (CNY) Revenue 284.98 M, Net Income 42.11 M, EPS 0.1058

View More

Stock List

Top Gainers

Top Decliners

Northbound Connect

Symbol

Price

%Chg

Change

View More